Relapsed Or Refractory Multiple Myeloma
BMYBristol-Myers SquibbCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Mezigdomide (CELMoD Modulator) in Relapsed Or Refractory Multiple Myeloma. The expected timing is based on the latest available company guidance and may change.
05/21/26:- Phase 3 SUCCESSOR-2 MeziKd results in R/R MM to be presented May 29, 2026. 05/28/26:- SUCCESSOR-2 Ph3 showed PFS benefit for MeziKd; ASCO 2026 late-breaking oral. Regulatory discussions planned. 07/13/26:- FDA accepted NDA for MeziKd in R/R MM; PDUFA May 13, 2027.
Verification
Confirm timing and program details against the company announcement or filing.